Editorial
Moving Towards the Future of Dyslipidemia Management
Abstract
The practice of clinical cardiology faces the continuous struggle of minimizing recurrent cardiovascular events by risk factor modification. Current clinical guidelines assist the practicing physician in these efforts. Two of the primary risk factors are that of cholesterol and overall adverse dyslipidemic burden. Current guidelines are based primarily on low density lipoprotein (LDL) reduction, when in fact the spectra of cholesterol particles are much larger. The role of these particles is a topic of intense investigation although much more data needs to be produced to further clarify their significance in primary cardiovascular events.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.